Melbourne, Australia, 31 July 2018: Sienna Cancer Diagnostics Ltd, (ASX:SDX) (“Sienna” or “the Company”), a medical technology company developing and commercialising innovative cancer related tests, is pleased to announce the successful completion of a $1.6m share placement which introduced an institutional investor to the register and increased the holding of a sophisticated investor. The funds raised will be used to accelerate the technology expansion program outlined in the Company’s strategic plan. Funds from the placement have now been received and a total of 27,039,349 shares were issued on 27 July 2018, making both Merchant Opportunities Fund and Mr David Williams substantial shareholders in the company.
For further information please download PDF attached:
Download this document
